Myeloma Novel Drug Discovery Ver 1.2
DISCO
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
1 other identifier
observational
250
1 country
1
Brief Summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 22, 2020
CompletedFirst Submitted
Initial submission to the registry
July 21, 2023
CompletedFirst Posted
Study publicly available on registry
August 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2033
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2035
August 3, 2023
August 1, 2023
12.6 years
July 21, 2023
August 1, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Cell viability
Myeloma cell viability when incubated with standard of care and novel compounds.
12 months
Study Arms (1)
Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.
Interventions
No intervention - blood and/or bone marrow sample collection only
Eligibility Criteria
Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
You may qualify if:
- Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- Participants aged 18 years of age or above
- Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
You may not qualify if:
- Participants unable to provide consent
- Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Royal Marsden NHS Foundation Trust
Sutton, SM25PT, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 21, 2023
First Posted
August 1, 2023
Study Start
July 22, 2020
Primary Completion (Estimated)
February 28, 2033
Study Completion (Estimated)
February 28, 2035
Last Updated
August 3, 2023
Record last verified: 2023-08